Navigation Links
mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical
Date:1/30/2008

- New Deal Advances the Company's Groundbreaking Smart Shape Memory Polymer

(BIO-SMP(TM)) Commercialization Program -

AACHEN, Germany, Jan. 30 /PRNewswire/ -- mNEMOSCIENCE GmbH, the pioneer in the design, manufacture and commercialization of innovative, biocompatible shape memory polymers (BIO-SMP(TM)), today announced the completion of a global licensing agreement for an application of the Company's BIO-SMP(TM) with Aporo Biomedical. Based in San Francisco, Aporo Biomedical is a medical device company dedicated to delivering transformative catheter-based technologies with an initial focus on cardiovascular and vascular therapeutic areas. Aporo Biomedical will use mNEMOSCIENCE's BIO-SMP(TM) in both patent foramen ovale (PFO) and femoral artery closure devices.

"We are delighted to partner with such a skilled and innovative medical device manufacturer for our BIO-SMP(TM) technology," said Christian Palme, CEO, mNEMOSCIENCE(R). "Securing high-quality, progressive partners like Aporo Biomedical has been a key focus of our strategic development plan and represents an important milestone in advancing our BIO-SMP(TM) commercialization program."

mNEMOSCIENCE has established an industry-leading technology platform for the design and manufacture of BIO-SMP(TM). The proprietary shape memory polymers developed by mNEMOSCIENCE are unlike any other materials currently being produced and can be programmed to change shapes and rigidity when an initiating stimulus, such as change in temperature through exposure to heat sources (e.g., the human body or liquids), application of light energy or a magnetic field, or pH-change in the surrounding environment is applied. Further programmable key features include varying rates of biodegradation, proven biocompatibility and outstanding mechanical properties, all of which may overcome the limitations of other currently used materials.

"Utilizing mNEMOSCIENCE's novel BIO-SMP(TM) technology and strong patent protection, Aporo is uniquely positioned to solve unmet medical needs by developing innovative trans-catheter and minimally invasive devices to facilitate healing, then biodegrade to leave no implant behind," commented Carolyn Patrick, CEO, Aporo Biomedical. "We look forward to working with the mNEMOSCIENCE team to bring these transformative devices to market."

Terms of the agreement were not disclosed.

About mNEMOSCIENCE GmbH

mNEMOSCIENCE GmbH, an intellectual property company and technology incubator, is a pioneer in the design, manufacture and commercialization of innovative biocompatible shape memory polymers (BIO-SMP(TM)) which may be applied to various industries such as medical devices, automotive, electronics, textiles or packaging, and may enable the development of groundbreaking products and therapies. Based in Aachen, Germany, the privately-held Company was founded in 1998 as a spin-off from Massachusetts Institute of Technology (MIT). With a robust international patent portfolio that provides broad exclusivity to the manufacture and use of these polymers, a history of innovation in the field, a strategic, market-conscious mentality, as well as an exclusive partnership with MIT, mNEMOSCIENCE is poised to remain at the vanguard of this new frontier. For more information, please visit http://www.mnemoscience.com or contact Ida Beerhalter, vice president, business development at businessdevelopment@mnemoscience.com.

About APORO Biomedical

Aporo Biomedical is a San Francisco Bay-area based medical device company dedicated to delivering transformative technologies for cardiovascular and vascular therapy. The Company seeks to leverage unique materials for devices to minimally invasively facilitate healing, and then biodegrade to leave no trace behind. The Company's initial area of focus is structural heart disease, including trans-catheter treatment of patent foramen ovale (PFO) and atrial septal defect (ASD). For more information, visit http://www.aporobiomedical.com.

Forward-Looking Safe Harbor Statement

With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of mNEMOSCIENCE GmbH could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products.

In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although mNEMOSCIENCE GmbH believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. mNEMOSCIENCE GmbH undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements."

BIO-SMP is a trademark of mNEMOSCIENCE GmbH.


'/>"/>
SOURCE mNEMOSCIENCE GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology:
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
Breaking Biology News(10 mins):